Amanda Nickles Fader, M.D., Joins Johns Hopkins As Director Of Gynecologic Oncology Service
Amanda Nickles Fader, M.D., a widely published and internationally recognized surgeon with a specialty in minimally invasive women’s cancer surgery and obesity and cancer, has joined Johns Hopkins Medicine as director of the Kelly Gynecologic Oncology Service and director of the Minimally Invasive Surgery Center in the Department of Gynecology and Obstetrics. She also holds the appointment of associate professor of gynecologic oncology at the Johns Hopkins University School of Medicine.
Fader has extensive training in the use of special laparascopes and robotics to perform complex gynecologic cancer operations. Prior to her appointment at Johns Hopkins, she served as an associate director of gynecologic oncology and director of robotic surgery at Greater Baltimore Medical Center.
"Amanda Fader is an outstanding surgeon, teacher and researcher," says Harold E. Fox, M.D., the Dorothy Edwards Professor and director of the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. “She will serve not only the needs of our patients and the department, but also those of the medical school, its students and faculty,” added Fox, who also serves as gynecologist/obstetrician-in-chief at The Johns Hopkins Hospital and Health System.
A graduate of the University of Virginia, Fader received her medical degree from the Medical College of Virginia and took postgraduate training at the Magee-Womens Hospital of the University of Pittsburgh Medical Center and at the Cleveland Clinic.
A board-certified gynecologic oncologist, Fader’s research focuses on minimally invasive surgical innovations, clinical trials with novel cancer treatments, high-risk endometrial cancer and the role of obesity in the development of women's cancers. Her research has been published in the Journal of Clinical Oncology, Cancer and the American Journal of Obstetrics & Gynecology. She has authored more than 65 peer-reviewed articles, and is the principal investigator on several clinical trials, including a randomized phase II trial of combination chemotherapy (carboplatin/paclitaxel) and an antibody drug (trastuzumab) for women with high-risk uterine cancer.
Fader says she has an increasing interest in the cancer-related consequences of the obesity epidemic and how women’s health care, and specifically cancer care, will evolve within the context of a changing health care landscape. She is among a group of researchers spearheading a national initiative to improve the quality of, and costs associated with, gynecologic cancer care through the establishment of health care standards and quality indicators used in the treatment of endometrial, ovarian and cervical cancers. Johns Hopkins will be one of 15 medical institutions involved in the effort.
She serves on the editorial board of Gynecologic Oncology and the Journal of Minimally Invasive Gynecology. Additionally, "Fader is active in the Gynecologic Oncology Group, has leadership roles in the Society of Gynecologic Oncology and American Association of Gynecologic Laparoscopy, and is also as a representative of Johns Hopkins to the National Comprehensive Cancer Network, where she serves on the endometrial and cervical cancer committees.